EC Number   |
Application |
Reference |
|---|
   1.6.2.2 | analysis |
detailed analysis of biphasic rate of reduction of cytochrome b5 in membranes with evaluation of data in terms of two-dimensional random walk model. The initial rapid phase is completed within 10 msec and over 90% of cytochrome b5 are reduced in 40 msec |
672516 |
| 1.6.2.2 | analysis |
microplate method based on a standard 96-well microplate format to simplify the quantification of NADH-CYB5R activity. Enzyme activity in 25 diagnosed cases of recessive congenital methemoglobinemia ranges from 6.09 to 10.07 IU/g Hb whereas normal control ranges from 13.42 to 21.58 IU/g Hb. Hemolysate samples have significant loss of activity when stored at 4°C and retain stable activity at -20°C for 1 week |
764815 |
| 1.6.2.2 | analysis |
potential use of the enzyme as biosensor |
724801 |
| 1.6.2.2 | diagnostics |
potential use of the enzyme in diagnostic areas |
724801 |
| 1.6.2.2 | drug development |
flavonoids, regarding b5 reductase inhibition, indicate a potential for significant flavonoiddrug and/or flavonoidxenobiotic interactions which may have important therapeutic and toxicological outcomes for certain drugs and/or xenobiotics. |
724717 |
| 1.6.2.2 | industry |
potential use of the enzyme in the food industry |
724801 |
| 1.6.2.2 | medicine |
- |
394246 |
| 1.6.2.2 | medicine |
enzyme and cytochrome b5 play a direct role in metabolic activation of antimicrobial prodrug DB289 to furamidine |
673289 |
| 1.6.2.2 | medicine |
isolation of mutations leading to type I recessive congenital methaemoglobinaemia |
672826 |
| 1.6.2.2 | medicine |
natural mutant P275L from a patient with recessive congenital methemoglobinemia shows significant decrease in the affinity toward the physiological reducing substrate, NADH, without affecting the activity |
671595 |
